The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-
mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis …

Background Multiple biologics for psoriasis exist, and interleukin (IL) 17 inhibitors are
among those with the best efficacy. However, switching treatment is often required at some …

Background: Psoriasis is a chronic immune-mediated inflammatory skin disease, with over-
activated interleukin (IL)-17-producing CD4+ T cells (Th17) and repressed regulatory T …

Risankizumab, a humanized immunoglobulin G1 monoclonal antibody, selectively inhibits
interleukin‐23, a key cytokine in the pathogenesis of psoriasis, by binding to its p19 subunit …

Mycoplasma infections, such as walking pneumonia or pelvic inflammatory diseases, are a
major threat to public health. Despite their relatively small physical and genomic size …

Introduction: Psoriasis is a chronic immune mediated disease in which the interplay of T
cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 …

Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the
natural history of numerous immune-mediated disorders, allowing the development of …

Psoriasis is a chronic inflammatory skin disease with unclear pathogenesis. Interleukin‐33
(IL‐33) is highly expressed in patients with psoriasis, but its role in psoriasis is unknown …

A variety of interleukin‐23 targeted drugs have been used to treat moderate to severe
psoriasis, but it is not clear which is most effective. This network meta‐analysis compared …

The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …